Friday 9th September 2022
Do you have scleroderma and have a weakened immune system? Would you like to have your say on whether a treatment which can prevent COVID-19 infection is made available to those who have poor immune responses in response to COVID-19 vaccination? Complete our short survey to inform our response to a NICE consultation on whether this treatment should be authorised for use.
Wednesday 7th September 2022
Would you like to find out more about a new study that aims to improve how we understand and treat fibrosis?
Tuesday 9th August 2022
72 people have signed up for this new trial for people living with diffuse scleroderma and now this clinical study, to test a new investigational drug for use in Diffuse Scleroderma, is ready to start.
Monday 1st August 2022
Evusheld is an antibody treatment designed to prevent patients from contracting COVID-19, and can provide protection for immunocompromised and immunosuppressed people that haven’t mounted a proper response to the vaccine. SRUK is supporting the call for the UK Government to procure and provide Evusheld to patients in the UK. Find out about how you can help on this page.
Friday 15th July 2022
July marks six months since Scleroderma & Raynaud’s UK launched STAR, the Symptom Tracking App for Raynaud’s, which enables members of the SRUK community to track their Raynaud's attacks and directly contribute to essential scientific research into the condition. Here’s a breakdown of what we’ve learnt so far, thanks to the STAR community!
Wednesday 29th June 2022
Tuesday 28th June 2022
On 29th June, Scleroderma & Raynaud’s UK will open applications for the Olive Ayoub Intermediate to Late-Stage Post-doctoral Research Fellowship, which will enable one exceptional, non-tenured post-doctoral researcher to transition from postdoc to research leader in the field of scleroderma.
Friday 24th June 2022
A new US study has found that scleroderma patients who test positive for ‘anti-Th/To antibodies’ are at higher risk of developing pulmonary hypertension (PH) in comparison to other patients, which could enable the earlier detection and more effective management of one of scleroderma’s most serious complications.
Friday 17th June 2022
Both of Alison's daughters have scleroderma, and having experienced the lack of understanding around the condition, she set out to help SRUK create a guide to scleroderma for schools.
Wednesday 8th June 2022
Yesterday saw the launch of the Innovative Medicines Fund (IMF) - a scheme which will give NHS patients living in England, including those with rare diseases like Scleroderma, the chance to have ‘early’ access to cutting-edge treatments offering them the best chances of a longer and healthier life.
